Rituximab Little Use in Resistant Idiopathic Nephrotic SyndromeDoctors LoungeThe anti-CD20 monoclonal antibody, rituximab, added to prednisone and calcineurin inhibitors, does not provide any additional benefit in terms of reduced proteinuria in the tr…
Personal struggle led to fundraising successWoodstock Sentinel ReviewEvery 14 to 21 months Ropp received Rituximab, a mild form of chemotherapy treatments that helped her go into a remission state. “They (the treatments) helped to get me off the ster…
Rituximab does not appear to benefit children with INSNews-Medical.netThe drug rituximab, an antibody that targets the immune system and is often used to treat immune disorders such as lymphoma and arthritis, has recently emerged as a potential treatme…
Clinical Oncology NewsNew Antibody Promising for Relapsed LymphomaClinical Oncology NewsSan Diego—In the first head-to-head comparison, obinutuzumab (GA101, Genentech) appeared to be more active than rituximab in relapsed CD20-positive indolent B-cel…
Immune drug doesn't help kids with hard-to-treat kidney disorderEurekAlert (press release)Children with a particular kidney immune disorder that is unresponsive to standard treatments do not benefit from the immune drug rituximab. Additional studie…
Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat …MarketWatch (press release)The EMA's Committee for Medicinal Products for Human Use ("CHMP") has accepted PIX306, CTI's ongoing randomized controll…
Pharmacyclics Reports Fiscal 2012 Third Quarter Financial Results and Recent …Sacramento BeeThe poster discussion session will highlight data from the ibrutinib Phase Ib CLL combination trial with bendamustine and rituximab in relapsed or refractory …
Clinical Oncology NewsCHOP-RIT, CHOP-R Similar for Follicular LymphomasClinical Oncology NewsSan Diego—Radiolabeled iodine-131 tositumomab (RIT) and rituximab have similar efficacy and tolerability when either is combined with CHOP (cyclophosphamide,…
Daiichi Sankyo teams up with US firm to develop biosimilarsMainichi Daily NewsDaiichi Sankyo will introduce relevant technology from Coherus BioSciences to develop biosimilar forms of etanercept for rheumatism treatment and rituximab for cancer treatme…
OncLiveMeeting the Challenges in Treating Lymphoma A Conversation With Andrew D …OncLiveDr Zelenetz: The standard of care for diffuse large B-cell lymphoma (DLBCL) in the United States remains rituximab (R) in combination with cyclophosphamide, doxor…